Effects of 17β-estradiol on proliferation, cell viability and intracellular redox status in native human lens epithelial cells

Molecular Vision

Volumn 17, Issue , 2011, Pages 1987-1996

  Celojevic, D ^a   Petersen, A ^a   Karlsson, J O ^a   Behndig, A ^b   Zetterberg, M ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; ESTRADIOL; GLUTATHIONE; PEROXIDE; SUPEROXIDE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CAPSULE OPACIFICATION; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIUM CELL; HUMAN; HUMAN CELL; LENS; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOSIS; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL;

APOPTOSIS; CASPASE 3; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; EPITHELIAL CELLS; ESTRADIOL; FLUORESCENT DYES; GLUTATHIONE; HUMANS; HYDROGEN PEROXIDE; LENS, CRYSTALLINE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEROXIDES; PRIMARY CELL CULTURE; PROPIDIUM; REACTIVE OXYGEN SPECIES; SUPEROXIDES;

EID: 79960712188     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Carlsson B, Sjostrand J. Increased incidence of cataract extractions in women above 70 years of age. A population based study. Acta Ophthalmol Scand 1996; 74:64-8.
2. Lundström M, Stenevi U, Thorburn W. Gender and cataract surgery in Sweden 1992-1997. A retrospective observational study based on the Swedish National Cataract Register. Acta Ophthalmol Scand 1999; 77:204-8.
3. Mönestam E, Wachtmeister L. Cataract surgery from a gender perspective-a population based study in Sweden. Acta Ophthalmol Scand 1998; 76:711-6.
4. Klein BE, Klein R, Linton KL. Prevalence of age-related lens opacities in a population. The Beaver Dam Eye Study. Ophthalmology 1992; 99:546-52.
5. Leske MC, Wu SY, Nemesure B, Yang L, Hennis A. Nine-year incidence of lens opacities in the Barbados Eye Studies. Ophthalmology 2004; 111:483-90.
6. Mitchell P, Cumming RG, Attebo K, Panchapakesan J. Prevalence of cataract in Australia: the Blue Mountains eye study. Ophthalmology 1997; 104:581-8.
7. Ostberg A, Loth A, Gustafson D, Lindblom B. Skovde cataract study: I. Prevalence of lens opacities in a Swedish community. Ophthalmology 2006; 113:970-5.
8. Klein BE. Lens opacities in women in Beaver Dam, Wisconsin: is there evidence of an effect of sex hormones? Trans Am Ophthalmol Soc 1993; 91:517-44.
9. Nirmalan PK, Robin AL, Katz J, Tielsch JM, Thulasiraj RD, Krishnadas R, Ramakrishnan R. Risk factors for age related cataract in a rural population of southern India: the Aravind Comprehensive Eye Study. Br J Ophthalmol 2004; 88:989-94.
10. Kahn HA, Leibowitz HM, Ganley JP, Kini MM, Colton T, Nickerson RS, Dawber TR. The Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol 1977; 106:17-32.
11. McCarty CA, Mukesh BN, Fu CL, Taylor HR. The epidemiology of cataract in Australia. Am J Ophthalmol 1999; 128:446-65.
12. Sperduto RD, Hiller R. The prevalence of nuclear, cortical, and posterior subcapsular lens opacities in a general population sample. Ophthalmology 1984; 91:815-8.
13. Cumming RG, Mitchell P. Hormone replacement therapy, reproductive factors, and cataract. The Blue Mountains Eye Study. Am J Epidemiol 1997; 145:242-9.
14. Freeman EE, Munoz B, Schein OD, West SK. Hormone replacement therapy and lens opacities: the Salisbury Eye Evaluation project. Arch Ophthalmol 2001; 119:1687-92.
15. Freeman EE, Munoz B, Schein OD, West SK. Incidence and progression of lens opacities: effect of hormone replacement therapy and reproductive factors. Epidemiology 2004; 15:451-7.
16. Klein BE, Klein R, Lee KE. Reproductive exposures, incident age-related cataracts, and age-related maculopathy in women: the beaver dam eye study. Am J Ophthalmol 2000; 130:322-6.
17. Younan C, Mitchell P, Cumming RG, Panchapakesan J, Rochtchina E, Hales AM. Hormone replacement therapy, reproductive factors, and the incidence of cataract and cataract surgery: the Blue Mountains Eye Study. Am J Epidemiol 2002; 155:997-1006.
18. Aina FO, Smeeth L, Hubbard R, Hurt LS, Fletcher AE. Hormone replacement therapy and cataract: a populationbased case-control study. Eye (Lond) 2006; 20:417-22.
19. Weintraub JM, Taylor A, Jacques P, Willett WC, Rosner B, Colditz GA, Chylack LT, Hankinson SE. Postmenopausal hormone use and lens opacities. Ophthalmic Epidemiol 2002; 9:179-90.
20. Worzala K, Hiller R, Sperduto RD, Mutalik K, Murabito JM, Moskowitz M, D'Agostino RB, Wilson PW. Postmenopausal estrogen use, type of menopause, and lens opacities: the Framingham studies. Arch Intern Med 2001; 161:1448-54.
21. Lindblad BE, Hakansson N, Philipson B, Wolk A. Hormone replacement therapy in relation to risk of cataract extraction: a prospective study of women. Ophthalmology 2010; 117:424-30.
22. Kanthan GL, Wang JJ, Burlutsky G, Rochtchina E, Cumming RG, Mitchell P. Exogenous oestrogen exposure, female reproductive factors and the long-term incidence of cataract: the Blue Mountains Eye Study. Acta Ophthalmol 2010; 88:773-8.
23. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999; 91:1829-46.
24. Harding JJ. Estrogens and cataract. Arch Ophthalmol 1994; 112:1511.
25. Beebe-Dimmer J, Morgenstern H, Cetin K, Yee C, Bartoces M, Shahinian V, Fryzek J, Acquavella J, Schwartz KL. Androgen deprivation therapy and cataract incidence among elderly prostate cancer patients in the United States. Ann Epidemiol 2011; 21:156-63.
26. Wang X, Simpkins JW, Dykens JA, Cammarata PR. Oxidative damage to human lens epithelial cells in culture: estrogen protection of mitochondrial potential, ATP, and cell viability. Invest Ophthalmol Vis Sci 2003; 44:2067-75.
27. Bigsby RM, Cardenas H, Caperell-Grant A, Grubbs CJ. Protective effects of estrogen in a rat model of age-related cataracts. Proc Natl Acad Sci USA 1999; 96:9328-32.
28. Hales AM, Chamberlain CG, Murphy CR, McAvoy JW. Estrogen protects lenses against cataract induced by ntransforming growth factor-beta (TGFbeta). J Exp Med 1997; 185:273-80.
29. Ninn-Pedersen K, Bauer B. Cataract patients in a defined Swedish population 1986-1990. VI. YAG laser capsulotomies in relation to preoperative and surgical conditions. Acta Ophthalmol Scand 1997; 75:551-7.
30. Santen RJ, Allred DC. The estrogen paradox. Nat Clin Pract Endocrinol Metab 2007; 3:496-7.
31. Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295:1647-57.
32. Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J, Santen RJ. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 2001; 93:1714-23.
33. Seilicovich A. Cell life and death in the anterior pituitary gland: role of oestrogens. J Neuroendocrinol 2010; 22:758-64.
34. Zetterberg M, Petersen A, Karlsson JO, Sundelin K. Proliferation of cultured lens epithelial cells and association with possible risk factors for posterior capsular opacification. European Association for Vision and Eye Research Conference; 2010 Oct 6-9; Hersonissos, Crete, Greece. Acta Ophthalmol (Copenh) 2010; 88:S246.
35. Spector A, Garner WH. Hydrogen peroxide and human cataract. Exp Eye Res 1981; 33:673-81.
36. Ramachandran S, Morris SM, Devamanoharan P, Henein M, Varma SD. Radio-isotopic determination of hydrogen peroxide in aqueous humor and urine. Exp Eye Res 1991; 53:503-6.
37. Moor AN, Gottipati S, Mallet RT, Sun J, Giblin FJ, Roque R, Cammarata PR. A putative mitochondrial mechanism for antioxidative cytoprotection by 17beta-estradiol. Exp Eye Res 2004; 78:933-44.
38. Kumar S, Lata K, Mukhopadhyay S, Mukherjee TK. Role of estrogen receptors in pro-oxidative and anti-oxidative actions of estrogens: a perspective. Biochim Biophys Acta 2010; 1800:1127-35.
39. Murphy AN. Ca(2+)-mediated mitochondrial dysfunction and the protective effects of Bcl-2. Ann N Y Acad Sci 1999; 893:19-32.
40. Borrás C, Sastre J, Garcia-Sala D, Lloret A, Pallardo FV, Vina J. Mitochondria from females exhibit higher antioxidant gene expression and lower oxidative damage than males. Free Radic Biol Med 2003; 34:546-52.
41. Gottipati S, Cammarata PR. Mitochondrial superoxide dismutase activation with 17 beta-estradiol-treated human lens epithelial cells. Mol Vis 2008; 14:898-905.
42. Strehlow K, Rotter S, Wassmann S, Adam O, Grohe C, Laufs K, Bohm M, Nickenig G. Modulation of antioxidant enzyme expression and function by estrogen. Circ Res 2003; 93:170-7.
43. Green PS, Simpkins JW. Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neurosci 2000; 18:347-58.
44. Cammarata PR, Chu S, Moor A, Wang Z, Yang SH, Simpkins JW. Subcellular distribution of native estrogen receptor alpha and beta subtypes in cultured human lens epithelial cells. Exp Eye Res 2004; 78:861-71.
45. Cammarata PR, Flynn J, Gottipati S, Chu S, Dimitrijevich S, Younes M, Skliris G, Murphy LC. Differential expression and comparative subcellular localization of estrogen receptor beta isoforms in virally transformed and normal cultured human lens epithelial cells. Exp Eye Res 2005; 81:165-75.
46. Colitz CM, Sugimoto Y, Lu P, Barden CA, Thomas-Ahner J, Chandler HL. ERalpha increases expression and interacts with TERT in cataractous canine lens epithelial cells. Mol Vis 2009; 15:2259-67.